Synopsis:- Joenja is the first drug approved in the U.S. for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Category:
Novartis
-
-
CompaniesIndiaMerger / AcquisitionNovartis
Dr. Reddy’s will Pay Rs 463 Crore for Novartis’ Cardiovascular Drug Cidmus (Valsartan +Sacubitril)
by adminby adminSummary Dr Reddy’s Laboratories, an Indian generic pharmaceutical company, has agreed to pay $61 million to Novartis AG for the cardiovascular brand…
-
CompaniesMerger / AcquisitionNovartis
Sandoz Acquires Drug Delivery Device Firm Coalesce
by adminby adminSummary : Sandoz acquired the capabilities and assets of drug delivery device company, Coalesce, to further its existing portfolio of respiratory medicines…
-
CompaniesNovartis
Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
by adminby adminSummary : Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER…
-
CompaniesGlobal MarketNovartis
Syncona announces sale of portfolio company to Novartis
by adminby adminSynopsis : Syncona – a company focused on founding, building and funding global leaders in life science – has announced the sale…
-
-
CompaniesGlobal MarketNovartis
Financials Indicate Novartis’ Sandoz Division Could Be a Tough Sell
by adminby adminSynopsis : Novartis reported its full-year financials this week for 2021, and overall, the news was good. Full-year net sales grew 4%,…
-
CompaniesGlobal MarketNovartis
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
by adminby adminSynopsis : Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep,…
-
CompaniesGlobal MarketNovartis
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent.
by adminby adminSynopsis: -Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US…
-
CompaniesNovartisRegulatoryU.S FDA
Novartis Cosentyx® Receives FDA Approval for the Treatment of Children and Adolescents with Enthesitis-Related Arthritis and Psoriatic Arthritis
by adminby adminSummary : -New approvals are based on JUNIPERA trial data showing Cosentyx® (secukinumab) demonstrated reduced flare risk versus placebo and improvement in…
Newer Posts